Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives

ClinicoEconomics and Outcomes Research · Published 2026-07-01 · DOI 10.2147/ceor.s626752

Free full text

Authors (6)

Jennifer E Vaughn, Nadine Zawadzki, Shurui Zhang, Paul Pinkston, David Wei, Jason Shafrin

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Vaughn, J., Zawadzki, N., Zhang, S., et al. (2026). Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives. ClinicoEconomics and Outcomes Research. https://doi.org/10.2147/ceor.s626752

Related articles